ArticleInfection and immunity1997
The lipopolysaccharide O side chain of Vibrio vulnificus serogroup E is a virulence determinant for eels.
Article in Infection and immunity, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 62 citations in OpenAlex.
- Comparative efficacy of Bacillus probiotics and formalin-killed bacterin against Vibrio anguillarum in European eel elvers.Scientific reports · 2026Article
- Vibrio vulnificus, an Underestimated Zoonotic Pathogen.Advances in experimental medicine and biology · 2023Review
- The Effect of the Environmental Temperature on the Adaptation to Host in the Zoonotic PathogenFrontiers in microbiology · 2020Article
- Article
- Host-nonspecific iron acquisition systems and virulence in the zoonotic serovar of Vibrio vulnificus.Infection and immunity · 2014Article
- Vibrio vulnificus biotype 2 serovar E gne but not galE is essential for lipopolysaccharide biosynthesis and virulence.Infection and immunity · 2008Article
- A common virulence plasmid in biotype 2 Vibrio vulnificus and its dissemination aided by a conjugal plasmid.Journal of bacteriology · 2008Article
- Identification of DNA sequences specific for Vibrio vulnificus biotype 2 strains by suppression subtractive hybridization.Applied and environmental microbiology · 2005Article
- Protocol for specific isolation of virulent strains of Vibrio vulnificus serovar E (biotype 2) from environmental samples.Applied and environmental microbiology · 2004Article
- Isolation of Vibrio vulnificus serovar E from aquatic habitats in Taiwan.Applied and environmental microbiology · 1999Article
- Comparative study of biological properties and electrophoretic characteristics of lipopolysaccharide from eel-virulent and eel-A virulent Vibrio vulnificus strains.Applied and environmental microbiology · 1999Article
- Heterogeneity among isolates of Vibrio vulnificus recovered from eels (Anguilla anguilla) in Denmark.Applied and environmental microbiology · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vibrio vulnificus is a gram-negative bacterium capable of producing septicemic infections in eels and immunocompromised humans. Two biotypes are classically recognized, with the virulence for eels being specific to strains belonging to biotype 2, which constitutes a homogeneous lipopolysaccharide (LPS)-based O serogroup (which we have designated serogroup E). In the present study we demonstrated that the O side chain of this LPS determines the selective virulence of biotype 2 for eels: (i) biotype 1 strains (which do not belong to serogroup E) are destroyed by the bactericidal action of nonimmune eel serum (NIS) through activation of the alternative pathway of complement, (ii) biotype 2 strains (of serogroup E) are resistant to NIS, and (iii) rough mutants of biotype 2 lacking the O polysaccharide side chain are sensitive to NIS and avirulent for eels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.